Drug Trial Radar · NCT03249207
SC IL-1Ra in SAH - Phase III Trial (SCIL)
Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
612
Actual
Start
Oct 11, 2018
Primary completion
Apr 2024
Study completion Sep 2024
Sponsor
- Lead sponsor
- University of ManchesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom; Clinical Trials Unit, Manchester; Northern Care Alliance NHS Foundation Trust
- First posted
- Aug 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial will establish whether IL-1Ra, with sub-cutaneous (SC) administration twice daily for up to 21 days post aneurysmal subarachnoid haemorrhage (aSAH), improves clinical outcome as measured by ordinal shift in mRS at 6 months. Patients with SAH transferred to a neurosurgical centre will be identified and approached for study participation. Following consent, patients will be randomised to receive either IL-1Ra or placebo for a maximum of 21 days from onset of symptoms. Patients who are found to be non-aneurysmal following randomisation will be withdrawn from the study treatment. Blood samples for plasma IL-6 will be obtained prior to randomisation and at day 3-5 post randomisation for IL-6 \& IL-1 measurement. Safety will be measured at 30 days post randomisation and outcome assessed at 6 months post randomisation.
Conditions
- Subarachnoid Hemorrhage
Interventions
IL-1RaDrug
Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
IL-1Ra PlaceboDrug
Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ordinal shift in modified Rankin Score (mRS)Time frame: 6 months post randomisation
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Royal Sussex County Hospital
Brighton, United Kingdom
Southmead Hospital
Bristol, United Kingdom
Addenbrookes Hospital
Cambridge, United Kingdom
The Walton Centre
Liverpool, United Kingdom
Royal London Hospital
London, United Kingdom
St George's Hospital
London, United Kingdom
Charing Cross Hospital
London, United Kingdom
National Hospital for Neurology and Neurosurgery, Queen Square
London, United Kingdom
Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom
Queens Medical Centre
Nottingham, United Kingdom
Royal Preston Hospital
Preston, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom
Derriford Hospital
Plymouth, Devon, United Kingdom
Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom
University Hospital of Wales
Cardiff, Wales, United Kingdom
Leeds General Infirmary
Leeds, Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.